Hepatitis C Articles (HCV)
Back
 
Genotype 3 at AASLD
AASLD:
All-Oral Treatment With Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study
- (11/23/15)
AASLD:
Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study
- (11/30/15)
AASLD:
Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients
- (11/16/15)
AASLD:
High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin
- (11/23/15)
AASLD:
Integrated Safety Analysis of Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, in Patients With HCV Genotype 3 Infection
- (12/03/15)
AASLD:
Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program (advanced liver disease)
- (12/03/15)
AASLD:
Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program
- (11/18/15)
AASLD:
Safety and Efficacy of Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Genotype 3 Infection: Interim Results of a Multicenter European Compassionate Use Program
- (11/16/15)
AASLD:
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection: Interim Analysis of a French Multicenter Compassionate Use Program
- (12/01/15)
EACS:
Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - Results from the German hepatitis C cohort (GECCO)
(10/27/15)
AASLD:
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (11/30/15)
View Older Articles
Back to Top
www.natap.org